TNBC


Also found in: Wikipedia.
AcronymDefinition
TNBCTriple Negative Breast Cancer (oncology)
TNBCThe Nightmare Before Christmas (1993 movie by Tim Burton)
TNBCTanzania National Business Council
TNBCTeen NBC (National Broadcasting Company, NBC)
TNBC'Twas the Night Before Christmas (stage play)
TNBCThe Northern Boys Club (UK)
TNBCThursday Night Book Club
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Roche's VENTANA PD-L1 (SP142) Assay is now CE marked and commercially available in the European Union as an aid for identifying patients with TNBC eligible for treatment with the Tecentriq combination.
The German pharma giant also said its Ventana PD-L1 Assay is now CE marked and commercially available in the EU as an aid for identifying patients with TNBC eligible for treatment with the Tecentriq combination.
The odds of diagnosis of TNBC were increased for diagnosis at American Joint Committee on Cancer stage III and beyond (odds ratios, 1.69 and 1.47 for stage III and stage IV, respectively).
(2014) identified mir-18b, mir-103, mir-107 and mir-652 as prognostic biomarkers for TNBC. Similarly, Liu et al.
KEYNOTE-119 is a Phase 3 randomised trial (ClinicalTrials.gov, NCT02555657) evaluating Keytruda monotherapy compared to single-agent physician's choice chemotherapy in metastatic TNBC.
The multicentre, dose-expansion, Phase 2a trial (AVID100-01; NCT03094169) will assess the efficacy, safety, and tolerability of AVID100 in patients with advanced, EGFR-overexpressing, TNBC (IHC 2+/3+).
According to the company, the companion diagnostic test approved by the US FDA for selecting TNBC patients for TECENTRIQ is the VENTANA PD-L1 (SP142) assay, which is an immunohistochemical assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor-infiltrating immune cells in formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
TNBC affects about 15 per cent of breast cancer patients.
TNBC affects 10-20 per cent of those who receive a breast cancer diagnosis.
Blocking the MDSCs themselves reduced tumor growth and metastasis in a mouse model of TNBC. The findings appeared in the Journal of Clinical Investigation.
Median DFS was 83.6 months in luminal A (95% CI 13.4-NE), 56.4 months (95% CI 34.3-99.7) in luminal B, 37 months (95% CI 8.5-20) in HER-2 positive, and 18.6 months (95% CI 6.7-NE) in TNBC patients (p=0.10).
Triple-Negative Breast Cancer (TNBC) is defined as negative for ER, PgR and HER-2/neu (with the finding of < 1% of tumour cell nuclei immunoreactive in immunohistochemistry, in the presence of the evidence of the sample that can express ER, PgR or HER-2/neu respectively as positive intrinsic controls).